The number of affiliates of major conglomerates under S. Korea's antitrust watch list increased by 24 to reach 2,325 as of the end of October, with the groups expanding investments in digital content and financial firms.
The transactions that increased new affiliates under tight restrictions include KT Corp.'s acquisition of K-Bank, an online bank, and a Naver Corp. affiliate establishing four digital content firms.
KT Corp. is South Korea's largest fixed-line internet operator, while Naver Corp. is the leading online portal operator.
The business groups launched or acquired 56 new affiliates while offloading 32 others.
Affiliates of large conglomerates with assets exceeding 10 trillion won are restricted under the South Korean fair trade law from making equity investments in co-affiliated companies or offering loan guarantees to each other.
The conglomerates are prohibited from engaging in excessive trading among affiliates and are required to make public filings on their non-listed affiliates.


Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
REPAY Stock Rises After Visa Platform Connect Collaboration
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 



